We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

91 hedge funds and large institutions have $140M invested in ADMA Biologics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 14

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

41% more call options, than puts

Call options by funds: $1.99M | Put options by funds: $1.41M

23% more funds holding

Funds holding: 74 → 91 (+17)

8% more capital invested

Capital invested by funds: $130M → $140M (+$9.86M)

1.39% more ownership

Funds ownership: 54.73% → 56.11% (+1.4%)

Holders
91
Holders Change
+17
Holders Change %
+22.97%
% of All Funds
2.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
27
Increased
41
Reduced
14
Closed
10
Calls
$1.99M
Puts
$1.41M
Net Calls
+$583K
Net Calls Change
+$604K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$17.5M
2
BlackRock
BlackRock
New York
+$4.59M
3
6CM
683 Capital Management
New York
+$4.49M
4
SFM
Sphera Funds Management
Israel
+$4.49M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.31M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$6.17M
2
MWVC
Morgens Waterfall Vintiadis & Co
New York
-$2.4M
3
SSA
Schonfeld Strategic Advisors
New York
-$1.79M
4
Jane Street
Jane Street
New York
-$443K
5
Millennium Management
Millennium Management
New York
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
– -$34K -8,506 Closed
1 2 3 4
5

ADMA Hedge Fund Activity: Q1 2020 in Review

91 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2020, worth a combined $140M — up 7.6% from $130M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ADMA positions and 10 closed out — a net gain of 17 holders — while 41 added to existing stakes and 14 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $17.5M. The largest seller was Consonance Capital Management, cutting an estimated $6.17M.

  • 91 institutional investors held ADMA Biologics (ADMA) as of Q1 2020, up from 74 in Q4 2019.
  • Funds reported $140M of ADMA Biologics stock for Q1 2020, up 7.6% quarter-over-quarter.
  • 27 funds opened new ADMA Biologics positions in Q1 2020 and 10 closed out, a net change of +17 holders.
  • The largest ADMA Biologics buyer in Q1 2020 was Perceptive Advisors, an estimated $17.5M added.
  • The largest ADMA Biologics seller in Q1 2020 was Consonance Capital Management, an estimated $6.17M sold.

Based on aggregated 13F filings for Q1 2020.